On Thursday, Roche Holdings AG (OTC:RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral that showed a reduction in the transmission of influenza viruses.
The study met its primary endpoint, demonstrating that a single oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus.
Also Read: Back-To-Back FDA Approvals For Roche’s Two Under-The-Skin Injections.
Xofluza was well tolerated, and no new safety signals ...
